Abstract
Since the onset of the global COVID-19 pandemic, there has been much discussion about the advantages and disadvantages of ongoing chronic drug therapies in SARS-CoV-2-positive patients. These discussions include also statins treatment. The statins are among the most widely used drugs in the global population. Statins aim to lower cholesterol, which is essential for many biological processes but can lead to heart disease if levels are too high; however, also the pleiotropic effects of statins are well known. So could the anti-inflammatory or the potential antiviral effects of statins be helpful in avoiding extreme inflammation and severity in COVID-19? To date, there are conflicting opinions on the effects of statins in the course of COVID-19 infection. The aim of this article is to describe the molecular and pharmacological basis of the pleiotropic effects of statins that could be more involved in the fight against COVID-19 infection and to investigate the current epidemiological evidence in the literature on the current and important topic.
Keywords: COVID-19; Pleiotropic effects; SARS-COV-2; Statins.
【저자키워드】 COVID-19, SARS-CoV-2, statins., Pleiotropic effects, 【초록키워드】 Treatment, Inflammation, therapy, Anti-inflammatory, COVID-19 pandemic, severity, drug, Antiviral effect, COVID-19 infection, statin, epidemiological, cholesterol, molecular, disease, statins, Evidence, Pleiotropic effects, Disadvantages, heart disease, disadvantage, Topic, SARS-CoV-2-positive patients, pharmacological, Effect, extreme, Course, include, involved, biological processe, chronic drug, pleiotropic effect, 【제목키워드】 statin, Effect,